The significant reduction in both phagocytic activity and cell proliferation upon HMGB2 knockdown suggests that HMGB2 could serve as a promising therapeutic target, not only for modulating immune responses but also for enhancing the efficacy of cancer treatments. Here, HMGB2 is linked to cancer.